

Clinical and functional efficiency assessment of complex treatment of macular edema caused by retinal vein occlusion
Heading: Тhematic supplement Article type: Original article
Authors: Zhayvoronok N.S., Egorov V.V., Smoliakova G.P., Danilova L.P., Emanova L.P., Povalyaeva D.A., Udovichenko E.M..
Organization: Postgraduate Institute for Public Health Workers, The S. Fyodorov Eye Microsurgery Federal State Institution
Purpose: to evaluate the effectiveness of combined ranibizumab and sulodexide use in treatment of macular edema (ME) cause by retinal vein occlusion (RVO). Material and Methods. During the study, we examined 40 patients with ME cause by RVO, not exceeding 1.5 months ago. All patients underwent standard ophthalmological examination, optical coherence tomography (ОСТ), ОСТ angiography and electrophysiological studies. To evaluate the effectiveness of the combined use of ranibizumab and sulodexide, all patients were divided into two groups. In patients of the first group (n=21), the first intravitreal injection of ranibizumab was supplemented with a course of sulodexide. Patients of the second group (n=19) did not receive sulodexide. Results. The degree of improvement in eye functions in patients of the first group, who received sulodexide in complex treatment, is due to the best level of restoration of the retinal microcir-culation in the macula due to increase in the capillary network density in the superficial and deep capillary plexus in the retina by more than 1.2 times and decrease foveal avascularzone area in 1.5 times in comparison with the initial state. Conclusion. The results of the study showed the high efficiency of the combined use of ranibizumab and sulodexide in the treatment of ME cause by RVO and allow to recommend their use to improve hemomicrocirculation in the macular retina and enhance visual functions.
Bibliography:
1. Boyko EV, Sosnovsky SV. Antiangiogenic therapy in ophthalmology. St. Petersburg: VMA, 2013; 292 p.
2. Tultseva SN, Astakhov YuS. The role of inflammation in the pathogenesis of macular edema: modern trends of medical treatment. Ophthalmology Journal 2012; 5 (4): 35-42.
3. Astakhov YuS, Petrishchev NN, Tultseva SN. Retinal vein thrombosis: etiology, pathogenesis, clinical picture, diagnosis, treatment. St. Petersburg: SPbGMU, 2005; 60 p.
4. Kiseleva TN. Ocular ischemic syndrome (clinical picture, diagnosis, treatment): DSc abstract. Moscow, 2001; 32 p.
5. Tultseva SN, Astakhov YuS. Retinal vein occlusion (etiology, pathogenesis, clinical picture, diagnosis, treatment). St. Petersburg: NLPubl.,2010; 112 p.
6. KhudyakovAYu, Sorokin EL. Analysis of long-term results of treatment of branch retinal vein occlusion. In: Makula-2010. Rostov-on-Don, 2010; p. 477-8.
7. Wong TY, Scott IU. Clinical practice: Retinal vein occlusion. N Engl J Med 2010; 363 (22): 2135-44.
8. Martin SC, Butcher A, Martin N, et al. Cardiovascular risk assessment in patients with retinal vein occlusion. Br J Ophthalmol 2002; 86 (7): 774-6.
9. Khan Z, Almeida DR, Rahim K, etal. 10-Year Framingham risk in patients with retinal vein occlusion: a systematic review and meta-analysis. Can J Ophthalmol 2013; 48 (1): 40-5.
10. Aghamirsalim M, Sorbi R, Naderian M, et al. Management of retinal vein occlusion, who is responsible? Acta Med Iran 2016; 54 (11): 731-6.
11. Cugati S, Wang JJ, Knudtson MD, et al. Retinal vein occlusion and vascular mortality. Ophthalmology 2007; 114 (3): 520-4.
12. Karia N. Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol 2010; (4): 809-16.
13. Pearse AK, Srinivas RS. Retinal vein occlusion and macular edema — critical evaluation of the clinical value of ranibizumab. Clin Ophthalmol 2011; (5): 771-81.
14. Danilova LP, Egorov VV, Smoliakova GP, et al. Clinical efficacy of complex using Lucentis and neuroprotective therapy in treatment of macular edema during retinal vein occlusion. Modern Technologies in Ophthalmology 2019; (2): 156-60.
15. Berger AR, Cruess AF, Altomare F, et al. Optimal treatment of retinal vein occlusion: Canadian expert consensus. Ophthalmologica 2015; 234 (1): 6-25.
16. Campochiaro PA, Pearlman SR, Brown DM. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the retain study. Ophthalmology 2014; 121 (1): 209-19.
17. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127(9): 1101-14.
18. Egorov EA, Astakhov YuS, Stavitskaya TV. Ophthalmic Pharmacology. Moscow: GEOTAR-Media, 2009; 592 p.
19. Zlobin IV Predicting the effectiveness of antiangiogenic treatment of macular edema caused by retinal vein occlusion: PhD abstract. Moscow, 2017; 23 p.
Attachment | Size |
---|---|
2021_02-1_295-300.pdf | 720.4 KB |